BPC-157 and TB-500 after shoulder surgery

Post-surgical recovery threads on r/peptides regularly feature BPC-157 and TB-500 alongside surgery plans for procedures like biceps tenodesis and rotator cuff repair. The interest is understandable: both compounds appear in preclinical tendon-healing literature, and the community has circulated anecdotal reports for years. What the animal data actually supports, and where it stops, is worth setting out clearly before surgery enters the picture.

What animal studies show

A 2025 systematic review in HSS Journal analysed 36 studies of BPC-157 in musculoskeletal injury, of which 35 were preclinical^[1]. Across rat and rabbit models of tendon rupture, ligament tear, and muscle injury, BPC-157 consistently improved functional, structural, and biomechanical outcomes. The proposed mechanism centres on enhanced growth-hormone receptor expression, upregulation of VEGF (vascular endothelial growth factor, the signalling protein that triggers new blood-vessel growth into damaged tissue), and suppression of inflammatory cytokines. A 2026 review in the American Journal of Sports Medicine covering injectable peptide therapies for orthopaedic indications reached a similar description: BPC-157 and thymosin beta-4 (the full-length precursor of the grey-market label TB-500) "promoted angiogenesis and tissue repair in preclinical models"^[2]. Neither review extends that finding to controlled human trials of shoulder or rotator cuff repair.

For TB-500, the picture is the same. The preclinical literature on thymosin beta-4 is substantial across dermal wound healing, cardiac repair, and corneal recovery. The only Western-standard human trial data sits in ophthalmology, where a topical eye-drop formulation (RGN-259) has run multiple Phase 3 trials for neurotrophic keratopathy and dry eye. That is a topical formulation studied in the eye, not a subcutaneous injection for shoulder surgery recovery. A 2025 narrative review titled "Regeneration or Risk?" noted that only three pilot studies have examined BPC-157 in humans at all, and the authors concluded the compound "should be considered investigational" until well-designed trials are completed^[3].

The human evidence gap

The HSS systematic review found exactly one human clinical study among its 36 included papers: a small retrospective case series in which 7 of 12 patients reported more than six months of pain relief following intra-articular BPC-157 injection for chronic knee pain^[1]. The case series lacked a control arm, used subjective self-report as the primary endpoint, and studied a different joint and indication from shoulder tendon repair. The authors recorded no clinical safety data from human use across the entire 36-study corpus.

A 2025 pilot study published in Alternative Therapies in Health and Medicine administered intravenous BPC-157 to two healthy adults across two sequential days and found no measurable effects on cardiac, hepatic, renal, thyroid, or glycaemic biomarkers. The authors described the result as encouraging but called for larger studies, noting that an n of 2 cannot characterise a safety profile. The US Department of Defense's Operation Supplement Safety programme, which reviews evidence for service members, concluded separately that "there is little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans."

The regulatory and doping picture

Neither BPC-157 nor TB-500 holds a marketing authorisation in the EU, EEA, UK, or US. The US DoD's Operation Supplement Safety lists BPC-157 explicitly as "an unapproved pharmaceutical agent" that cannot be legally prescribed^[4]. Both compounds appear on the World Anti-Doping Agency Prohibited List: BPC-157 under S0 (non-approved substances) and TB-500 under S2 (peptide hormones, growth factors and related substances). For anyone subject to sport drug-testing, using either compound around surgery carries a real sanctions risk. For anyone not subject to sport testing, the relevant question is that neither compound has been through the regulatory evaluation a new drug requires.

The US FDA Pharmacy Compounding Advisory Committee was scheduled to review BPC-157's eligibility as a bulk compounding substance in July 2026. Whatever the outcome, that process addresses what compounding pharmacies may prepare, not whether BPC-157 has been shown to be safe or effective in humans. Compounding eligibility is not marketing authorisation, and the underlying evidence gap does not close on a committee vote.

What this means for surgery planning

Surgeons planning a biceps tenodesis and rotator cuff repair work with established post-operative protocols grounded in decades of clinical evidence. Introducing grey-market peptides into that plan adds variables that are essentially uncharacterised in the human surgical setting: no validated dosing range, no confirmed interaction profile with anaesthetics or post-operative pain management, no data on immune or inflammatory effects in the specific context of tendon reattachment, and no quality assurance on what is actually inside a grey-market vial. The 2026 orthopaedic review in the American Journal of Sports Medicine was direct on this point: "significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients"^[2]. The detail on the regulatory status of each compound in your country is on the BPC-157 regulation page and the TB-500 regulation page.

If you are considering either compound alongside planned orthopaedic surgery, that conversation belongs with your surgeon and your prescribing clinician before any decision is made. They are the people who know your specific procedure, your concurrent medications, and your risk profile. This article is for educational purposes and does not constitute medical advice.